A pharmacokinetic and bioequivalence study of adalimumab biosimilar (CHS-1420)

Trial Profile

A pharmacokinetic and bioequivalence study of adalimumab biosimilar (CHS-1420)

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Psoriasis; Rheumatoid arthritis
  • Focus Pharmacokinetics; Registrational
  • Most Recent Events

    • 02 Mar 2017 Results published in a Coherus Biosciences media release.
    • 02 Mar 2017 Primary endpoint (Area under the time-concentration curve from first time point extrapolated to infinity (AUC0-inf)) has been met, according to a Coherus Biosciences media release.
    • 02 Mar 2017 Primary endpoint (Maximum serum concentration (Cmax)) has been met, according to a Coherus Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top